Capricor Therapeutics (NASDAQ:CAPR) Trading Up 11% – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price was up 11% on Thursday . The company traded as high as $9.73 and last traded at $9.4990. 1,539,920 shares traded hands during trading, a decline of 49% from the average session volume of 3,049,009 shares. The stock had previously closed at $8.56.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Capricor will present HOPE-3 and open-label extension data for deramiocel at the World Muscle Society Congress from September 29 to October 3. The late-breaking data will include delayed-start and natural-history analyses submitted in a recent major amendment to the biologics license application. The FDA’s PDUFA target action date is November 22, 2026, giving investors a near-term regulatory catalyst. Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data
• Positive Sentiment: B. Riley Financial raised Capricor to “Buy,” while the reported analyst consensus price target was increased to $21.42. These ratings suggest some analysts see substantial recovery potential following the stock’s earlier decline. Capricor Therapeutics Raised to Buy at B. Riley Financial
• Neutral Sentiment: Several law firms are soliciting investors to seek lead-plaintiff status by September 28 in a pending federal securities class action covering purchases made primarily between December 17, 2025, and July 26, 2026. The notices repeat allegations concerning HOPE-3 trial blinding, protocol procedures and differences between the final protocol and statistical analysis plan; these are allegations, not findings of wrongdoing. CAPR Deadline Alert
• Negative Sentiment: The volume of lawsuit announcements reinforces legal, reputational and potential financial uncertainty surrounding Capricor after the reported sharp stock decline following FDA briefing documents and an adverse advisory committee vote. Investors may remain cautious ahead of the FDA decision and upcoming trial-data presentation. CAPR Upcoming Deadline

Wall Street Analyst Weigh In

Several research firms recently commented on CAPR. Maxim Group lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Roth Capital lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target on the stock. in a research note on Monday, July 27th. Piper Sandler raised shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Tuesday, September 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Friday, September 11th. Finally, Oppenheimer upgraded shares of Capricor Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, August 25th. Five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $30.25.

Capricor Therapeutics Trading Up 10.3%

The stock’s 50-day moving average is $10.23 and its 200-day moving average is $22.77. The stock has a market cap of $549.13 million, a price-to-earnings ratio of -3.85 and a beta of 0.72.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). On average, equities analysts predict that Capricor Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Anthony Bergmann sold 24,100 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the sale, the chief financial officer directly owned 11,223 shares in the company, valued at approximately $340,954.74. This represents a 68.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 25,000 shares of company stock worth $759,158. 9.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of CAPR. KBC Group NV purchased a new position in Capricor Therapeutics in the 1st quarter valued at about $44,000. ACT Capital Management LLC acquired a new position in shares of Capricor Therapeutics in the fourth quarter worth about $43,000. Allworth Financial LP boosted its holdings in Capricor Therapeutics by 5,021.5% in the fourth quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 3,264 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Capricor Therapeutics during the 1st quarter valued at approximately $193,000. Finally, Focused Wealth Management Inc purchased a new stake in Capricor Therapeutics during the 1st quarter worth approximately $203,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell- and exosome-based therapies for serious diseases. The company’s programs are designed to use regenerative medicine and targeted delivery technologies to address conditions with limited treatment options.

Its leading therapeutic candidate is deramiocel, also known as CAP-1002, an allogeneic cell therapy derived from cardiosphere-derived cells. The program has been studied primarily for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and cardiac complications.